Lancet Neurology Impact Factor

The first signal is obvious: Lancet Neurology is operating at true flagship level in clinical neurology.

The second signal is durability. The five-year JIF of 56.2 is even higher than the two-year JIF, which suggests the journal's strongest papers keep influencing the field beyond the immediate citation window.

The third signal is normalized strength. The JCI of 12.19 is exceptionally high.

The fourth signal is cleanliness. The JIF without self-cites is 44.6, only slightly below the headline number.

The practical reading is that the journal combines citation power with a very narrow idea of what counts as a publishable flagship clinical neurology paper.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is down from 10.24 in 2023 to 10.20 in 2024. That is a very small year-over-year change, not a structural drop.

The more important point is that the official JCR row remains at a very high level and still leads the category. In practice, authors should read the trend as sustained flagship authority rather than a journal losing relevance.

The common mistake is to read Lancet Neurology as simply the highest-impact neurology option.

That is too abstract to be useful. The journal wants clinically decisive papers that matter to a broad neurology audience. Many very strong neurology studies do not have that shape.

Papers often miss here when they are:

• strong but too specialist for general neurologists
• technically rigorous without a clear practice implication
• translational or basic neuroscience stories without a firm clinical bridge
• important within one disease lane but not broad enough for a flagship clinical journal

The number says the journal is elite. It does not say the paper has flagship clinical breadth.

In our pre-submission review work with manuscripts targeting Lancet Neurology, three patterns show up repeatedly.

The paper is too narrow for a flagship readership. Some disease-specific neurology manuscripts are excellent but do not travel widely enough across clinical neurology.

The clinical consequence is implied rather than demonstrated. Editors want the practical change case to be visible in the results, not built mainly in the discussion.

The study is more translational than clinical. Good neuroscience can still miss if the bridge to actual neurological management is not strong enough yet.

If that sounds familiar, a Lancet Neurology submission readiness review is usually more valuable than another surface-level revision.

The current Lancet institutional access materials add a useful non-JCR signal: the journal markets itself as the world-leading clinical neurology journal, cites the 45.5 impact factor, and also highlights a CiteScore of 62.6 with a 1/400 rank in neurology (clinical).

That matters because it shows the journal is not only strong by JCR logic. It is also positioned for very broad clinical-neurology visibility across another major metric system. For authors, that usually means the journal expects papers that travel beyond one disease lane and still matter to neurologists who do not work mainly in that niche.

The impact factor does not tell you whether the paper is broad enough, whether the clinical action is explicit enough, or whether the real audience is a strong but less flagship neurology journal.

Those are the actual editorial screens.